- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- January 2024
- 216 Pages
United States
From €3565EUR$3,750USD£2,995GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2614EUR$2,750USD£2,196GBP
- Report
- March 2022
- 324 Pages
Global
From €9031EUR$9,500USD£7,587GBP
Xaracoll is a type of analgesic, or pain reliever, that is used to treat moderate to severe pain. It is a long-acting, injectable form of bupivacaine, a local anesthetic. Xaracoll is administered via a subcutaneous injection, and its effects can last up to 72 hours. It is used to treat post-operative pain, as well as chronic pain conditions such as osteoarthritis and low back pain. Xaracoll is also used to treat pain associated with cancer and other medical conditions.
Xaracoll is a relatively new analgesic, and the market is still in its early stages. It is expected to grow in the coming years, as more people become aware of its potential benefits. The market is highly competitive, with several companies offering Xaracoll products. Some of the major players in the Xaracoll market include Pacira Pharmaceuticals, Inc., Endo Pharmaceuticals, Inc., and Mylan N.V. Show Less Read more